Comprehensive pharmacologic therapy for treatment of obesity

Abstract

The comprehensive pharmacologic therapy for treatment of obesity is a procedure which involves the administration of a desired therapeutic range of Diethylpropion and/or Phentermine in combination with a SSRI medication and nutritional supplementation for brief and long durations which may be 12 months or more. The preferred procedure involves the administration of drugs in combination which are identified as: Citalopram (Celexa) and Phentermine; Citalopram (Celexa) and Diethylpropion; Citalopram (Celexa), Phentermine, and Diethylpropion. In addition nutritional supplementation such as a multivitamin, 5-Hydroxytryptophan, vitamin B6, vitamin C, Tyrosine, Calcium, and Lysine may be used to enhance the performance of the weight loss treatment program.

1 . A nutritional supplement preparation for consumption by a patient comprising: 
 5-hydroxytryptophan and tyrosine;    wherein the amount of 5-hydroxytryptophan is from about 50 mg to about 900 mg and the amount of tyrosine is from about 50 mg to about 4000 mg.    
     
     
         2 . The nutritional supplement preparation of  claim 1  further comprising at least one cofactor or nutrient selected from the group consisting of vitamin C, vitamin B6, calcium, and Lysine.  
     
     
         3 . The nutritional supplement preparation of  claim 2  wherein the cofactor or nutrient is vitamin C.  
     
     
         4 . The nutritional supplement preparation of  claim 3  wherein the amount of vitamin C is from about 50 mg to about 2000 mg.  
     
     
         5 . The nutritional supplement preparation of  claim 2  wherein the cofactor or nutrient is vitamin B6.  
     
     
         6 . The nutritional supplement preparation of  claim 5  wherein the amount of vitamin B6 is from about 2 mg to about 150 mg.  
     
     
         7 . The nutritional supplement preparation of  claim 2  wherein the cofactor or nutrient is calcium.  
     
     
         8 . The nutritional supplement preparation of  claim 7  wherein the amount of calcium is from about 50 mg to about 2000 mg.  
     
     
         9 . The nutritional supplement preparation of  claim 2  wherein the cofactor or nutrient is Lysine.  
     
     
         10 . The nutritional supplement preparation of  claim 9  wherein the amount of Lysine is from about 50 mg to about 2000 mg.  
     
     
         11 . The nutritional supplement preparation of  claim 1  further comprising vitamin C, vitamin B6, calcium, and Lysine.  
     
     
         12 . The nutritional supplement preparation of  claim 11  wherein the amount of vitamin C is from about 50 to about 2000 mg, the amount of vitamin B6 is from about 2 mg to about 150 mg, the amount of calcium is from about 50 mg to about 2000 mg, and the amount of Lysine is from about 50 mg to about 2000 mg.  
     
     
         13 . The nutritional supplement preparation of  claim 1  wherein the nutritional supplement preparation is a pill.  
     
     
         14 . The nutritional supplement preparation of  claim 1  wherein the amount of 5-hydroxytryptophan is from about 200 mg to about 900 mg and the amount of tyrosine is from about 200 mg to about 4000 mg.  
     
     
         15 . The nutritional supplement preparation of  claim 1  wherein the amount of 5-hydroxytryptophan is from about 300 mg to about 700 mg and the amount of tyrosine is from about 500 mg to about 4000 mg.  
     
     
         16 . The nutritional supplement preparation of  claim 1  wherein the amount of 5-hydroxytryptophan is from about 300 mg to about 700 mg and the amount of tyrosine is from about 1000 mg to about 4000 mg.  
     
     
         17 . A nutritional supplement therapy system comprising: 
 a nutritional supplement preparation comprising 5-hydroxytryptophan, tyrosine, and at least one cofactor or nutrient selected from the group consisting of vitamin B6, vitamin C, calcium, and Lysine; and    a nutritional supplement dosing instruction indicating dosages of the nutritional supplement for consumption by a person in a single day and a maximum dosage per day.    
     
     
         18 . The nutritional supplement therapy system of  claim 17  wherein the nutritional supplement dosing instruction provides for about 50 mg to about 900 mg of 5-hydroxytryptophan per day.  
     
     
         19 . The nutritional supplement therapy system of  claim 17  wherein the nutritional supplement dosing instruction provides for about 50 mg to about 4000 mg of tyrosine per day.  
     
     
         20 . The nutritional supplement therapy system of  claim 17  further comprising a dosage of at least one pharmaceutical selected from the group consisting of Citalopram, Phentermine, and Diethylpropion.  
     
     
         21 . The nutritional supplement therapy system of  claim 17  wherein the nutrient or cofactor is vitamin B6 and the nutritional supplement dosing instruction provides for about 2 mg to about 150 mg of vitamin B6 per day.  
     
     
         22 . The nutritional supplement therapy system of  claim 17  wherein the nutritional supplement preparation and the nutritional supplement dosing instruction assist in effectuating weight loss.  
     
     
         23 . The nutritional supplement therapy system of  claim 17  wherein the nutritional supplement preparation and the nutritional supplement dosing instruction are directed to treatment of neurotransmitter deficiency.  
     
     
         24 . A method of administering a nutritional supplement preparation for treating neurotransmitter deficiency in a patient, the method comprising providing for a daily consumption, simultaneously or separately, from about 190 mg to about 900 mg of 5-hydroxytryptophan and from about 50 mg to about 4000 mg of tyrosine.  
     
     
         25 . The method according to  claim 24  further comprising providing from about 2 mg to about 150 mg of vitamin B6.  
     
     
         26 . The method according to  claim 24  further comprising providing from about 50 mg to about 2000 mg of vitamin C.  
     
     
         27 . The method according to  claim 24  further comprising providing from about 50 mg to about 2000 mg of Lysine.  
     
     
         28 . The method according to  claim 24  further comprising providing from about 50 mg to about 2000 mg of calcium.  
     
     
         29 . The method of according to  claim 24  further comprising providing at least one pharmaceutical selected from the group consisting of Citalopram, Phentermine, and Diethylpropion.  
     
     
         30 . A method of treating neurotransmitter deficiency in a patient, the method comprising: 
 providing an effective therapeutic amount of 5-hydroxytryptophan and an effective therapeutic amount of tyrosine to control neurotransmitter deficiency;    wherein the effective therapeutic amount of 5-hydroxytryptophan is from about 50 mg to about 900 mg and the effective therapeutic amount of tyrosine is from about 50 mg to about 4000 mg.    
     
     
         31 . The method according to  claim 30  further comprising providing an effective therapeutic amount of vitamin B6; wherein the effective therapeutic amount of vitamin B6 is from about 2 mg to about 150 mg.  
     
     
         32 . The method according to  claim 30  further comprising providing an effective therapeutic amount of vitamin C; wherein the effective therapeutic amount of vitamin C is from about 50 mg to about 2000 mg.  
     
     
         33 . The method according to  claim 30  further comprising providing an effective therapeutic amount of Lysine; wherein the effective therapeutic amount of Lysine is from about 50 mg to about 2000 mg.  
     
     
         34 . The method according to  claim 30  further comprising providing an effective therapeutic amount of vitamin calcium; wherein the effective therapeutic amount of calcium is from about 50 mg to about 2000 mg.  
     
     
         35 . The method according to  claim 30  further comprising providing an effective therapeutic amount of at least one pharmaceutical selected from the group consisting of Citalopram, Phentermine, and Diethylpropion.